How m6A Modification Affects Coxsackievirus B1 in Human Beta Cells
Author Information
Author(s): Bonfim Maressa Fernandes, Aitchedji Camille, Van Goethem Flore, Sauvage Lionel, Poinsot Thibault, Calonne Emilie, Deplus Rachel, Fuks François, Eizirik Decio L., Op de Beeck Anne
Primary Institution: ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles, Brussels, Belgium
Hypothesis
The N6-methyladenosine RNA epigenetic modification machinery regulates CVB1 amplification in human pancreatic beta cells.
Conclusion
The study provides evidence that m6A modification directly affects the production of coxsackievirus B1 in human pancreatic beta cells.
Supporting Evidence
- The downregulation of m6A writers increases CVB1 amplification in human pancreatic beta cells.
- The silencing of m6A erasers reduces CVB1 amplification in EndoC-βH1 cells.
- Inhibition of FTO significantly reduces the production of infectious CVB1.
- FTO inhibition affects CVB1 translation and replication at early time points post-infection.
Takeaway
This study shows that a special chemical change in RNA called m6A can help the coxsackievirus grow in human cells that make insulin, which is important for diabetes.
Methodology
The study used small interfering RNA (siRNA) to target m6A writers and erasers in human pancreatic beta cells and assessed the impact on CVB1 amplification.
Limitations
Potential off-target effects from siRNA silencing may influence the interpretation of results.
Statistical Information
P-Value
p<0.0005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website